1Chen SJ,Jiaang WT. Current advances and therapeutic potential of a-gents targeting dipeptidyl peptidase-IV,-II,8/9 and fibroblast actionprotein. Curr Top Med Chem,2011 ,11:1447-1463.
2Azuma K,Radikova Z,Mancino J,et al. Measurements of islet functionand glucose metabolism with the DPP-4 inhibitor vildagliptin in patientswith type 2 diabetes. Clin Endocrinol Metab,2008 ,93 :459-464.
3Ayala JE,Bracy DP,Hansotia T,et al. Insulin action in the donble in-cretin receptor knockout mouse. Diabetes,2008,57:288-297.
4Lamont BJ, Drucker DJ. Differential antidiabetic ef? cacy of incretin ag-onists versus DPP-4 inhibition in high fat fed mice. Diabetes,2008,57:190-198.
5Dobrian AD,Ma Q,Lindsay JW,et al. Dipeptidyl peptidase IV inhibitorsitagliptin reduces local inflammation in adipose tissue and in pancreaticislets of obese mice. Endocrinology and metabolism,2011,300:410-421.
6Chinda K,Palee S,Surinkaew S,et al. Cardioprotective effect of dipepti-dyl peptidase-4 inhibitor during ischemia-reperfusion injury. Int J Cardi-ol,2012,26: Epub ahead of print.
7Pi-Sunver FX, Schweiser A, Mills D, el al. Efficacy and tolerability ofvildagliptin monotherapy in drug-naive patients with type 2 diabetes. Di-abetes Res Clin Pract ,2007,76 : 132-138.
8Schweizer A, Dejager S, Bosi E, et al. Comparison of vildagliptin andmetformin monotherapy in elderly patients with type 2 diabetes : a 24-week ,double-blind, randomized trial. Diabetes Obes Metab, 2009 ,11:804-812.
9Rosenstock J,Aguilar-Salinas C,Klein E, et al. Effect of saxagliptinmonotherapy in treatment-naive patients with type 2 diabetes. Curt MedRes 0pin,2009,25 :2401-2411.
10SeekT,Nauck M,Sheng D,et al. Safety and efficacy of treatment withsitagliptin or glipizide in patients with type 2 diabetes inadequately con-trolled on metformin : a 2 year study. Int J Clin Pract, 2011,64:562-576.
2Lehy JL. Pathogenesis of Type 2 diabetesmellitus. Arch Med Res, 2005, 36 : 197-209.
3Azuma K, Radikova Z, Maneino J, et al. Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vilda-gliptin in patients with type 2 diabetes. J Chin Endocrinol Metab,2008, 93:459-464.
4Bosehmann M, Engeli S, Dobberstein K, et al. Dipeptidyl-peptidase-I V inhibition augments postprandial lipid mobilization and oxidation in type 2 diabetic patients. Clin Endocrinol Metab ,2009,94:846-852.
5Ivanon KP,Mychka VB. Perspectives of impaired glucose tolerance man- agement in patients with metabolic syndrome. Cardiovase Ther Preven- tion,2011,10:77-82.
6Van Poppel PC, Netea MG ,Smits P ,et al. ViIdagliptin improves endothe- lium-dependent vasodilatationin type 2 diabetes. Diabetes Care, 2011, 34 : 2072 -2077.
7Ahren B. Emerging dipeptidyl peptidnse-4 inhibitors for the treatment of diabetes. Emerging Drugs ,2008,13 : 593-607.
8Nauck M, Meininger G, Sheng D,et al. Efficacy and u f the safety of the dipep tidyl peptidaae-4 inhibitor, sitagliptin, compared to the sulphony- hrea in patients with type 2 diabetes in adequately controlled on met- formin alone : a randomized double-blind, non--infedofity trial. Diabetes Obes-Metah ,2007,9 : 194-205.
9Shaw JE,Sicree RA,Zimmet PZ.Global estimates of the prevalence of diabetes for 2010 and 2030[J].Diabetes Res Clin Pract,2010,87(1):4-14.
10Baetta R,Corsini A.Pharmacology of dipeptidyl peptidase-4 inhibitors:similarities and differences[J].Drugs,2011,71 (11):1441-1467.
